Search PubMed⌕ Search

Biomedical subjects

U Patzold

Publications and source records attributed to U Patzold.

At least 37 records · Page 2Linked to original sources
PubMed1982

Azathioprine in treatment of multiple sclerosis. Final results of a 41/2-year controlled study of its effectiveness covering 115 patients.

In an open, randomised, controlled follow-up study the effectiveness of continuous azathioprine therapy of multiple sclerosis with a dosage of 2 mg/kg/day was tested against a control group that was not treated with cytostatics. In the treated group the disease progressed less rapidly than in the untreated group. Statistically significant differences were only seen in patients having an intermittent-progressive course. The effect of azathioprine on the course was not dependent on the period or severity of illness nor on the patient's sex. In chronically progressive disease and with an intermittent disease course no influence of azathioprine was observed.

Adult↗
PubMed1982

Course of multiple sclerosis. First results of a prospective study carried out of 102 MS patients from 1976-1980.

The course of multiple sclerosis was monitored by means of a long-term prospective study. This paper reports on first results from this study, covering 102 patients who were monitored for 2 years or more and examined regularly. It is attempted to quantify the extent of the worsening or improvement in the patients' clinical status over the period of observation using regression analysis techniques. The severity of the disease did not correlate to the period of observation in 15% of the cases, these displaying no progression with regard to the clinical signs. In most cases (32%) a description of the disease progression was possible by means of a linear regression line, 21% had a parabolic and 23.5% an increasingly progressive course. For nine patients a second or third degree polynomial regression curve could be used to describe the course of the disease. The individual progression of the disease as estimated using the linear regression coefficient did not correlate with the individual relapse rate (on average 1.1 per year), nor with the age of the patient, the severity of the multiple sclerosis, the duration of the illness or with the previous course of the disease.

Adult↗
PubMed1980

Immune complexes in multiple sclerosis: relation to clinical pattern.

Using a C1q binding test, circulating immune complexes (IC) were detected in 33.3% of sera from 138 patients and in 19.4% of 124 spinal fluid samples from patients with multiple sclerosis. Most often they occur in sera alone. As a rule their detectable amount is small in sera as well as in spinal fluids. IC were observed with equal frequency during acute exacerbations and in stable phases of the disease. In patients with early MS of less than 3 months duration, IC were detected only rarely, whereas their frequency increased up to 50% in patients with longer standing disease. Immunosuppressive therapy has no influence on IC formation. Patients with immune complexes exhibited a more rapid clinical deterioration if compared as a group with IC-negativ ones. No correlations were found between immune complex formation and the CSF-IgG index or the rate of pleocytosis in spinal fluids. Neither the complement factors C3, C4, C3A nor total hemolytic complement activities (CH50) in serum were significantly decreased in patients with IC formation in serum as compared with the IC-negative group. The results demonstrate that IC formation probably is of no importance in the pathogenesis of multiple sclerosis.

Acute Disease↗
PubMed1980

Azathioprine in multiple sclerosis--a 3 year controlled study of its effectiveness.

The results of a prospective, long-term controlled study on the treatment of multiple sclerosis with azathioprine are reported. The effect of a daily 2 mg/kg body weight dosage on 56 randomly chosen patients with multiple sclerosis is compared with a non-treated control group of 51 randomly selected multiple sclerosis patients. The azathioprine therapy was continued in all cases for more than one year, on average for 732 days. To assess the effect of therapy, the course of the disease was followed by regular examinations evaluating the severity of the disease by use of an objective weighting-scale covering the whole range of neurological signs. The individual course of the disease within the observation period was determined by means of regression analysis. On average, the disease deteriorated less rapidly for those undergoing azathioprine therapy, this being most marked for patients who had had the disease for less than two years. For those who had been affected for longer, no significant differences in the progression of the disease could be detected. The annual relapse rate was the same for both categories.

Adult↗
PubMed1979

Cerebrospinal fluid immune complexes in multiple sclerosis.

Using a C1q binding test, immune complexes have been detected in one half of cerebrospinal fluid samples from patients with multiple sclerosis. These results provide additional evidence for the participation of an immune reaction in the disease process.

Antigen-Antibody Complex↗